Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
Deutsche Version Deutsche Version
  MedUni Vienna    Intranet    MedUni Vienna - Shop    University Library    University Hospital Vienna  
 
Krebsforschung_EN.png
 
 
 
Hauptnavigation
  • Home
  • General Information
    • History
    • 50 years Institute for Cancer Research
    • Imagevideo: Institute for Cancer Research
  • Research
    • Research Focus
    • Research Laboratories
    • Scientific Services - Core Facilities
  • Teaching
    • Lectures of the Institute of Cancer Research
    • University Course Toxicology for Postgraduates
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Program Malignant Diseases
    • PhD Program Clinical and Experimental Oncology
  • Contact
    • Contact
    • Map
 
Research / Research Focus / Applied and Experimental Oncology / Walter Berger
 
Subnavigation
  • Research Focus
    • Cellular and Molecular Tumorbiology
    • Applied and Experimental Oncology
      • Walter Berger
        • Research Projects
        • Group Members
      • Martin Filipits
      • Petra Heffeter
      • Michael Grusch
      • Klaus Holzmann
      • Hedwig Sutterlüty
    • Chemical Safety and Cancer Prevention
    • Tumor Progression and Metastasis
  • Research Laboratories
  • Scientific Services - Core Facilities


Inhaltsbereich

 

Walter Berger, Univ.-Prof. Mag. Dr.
Coordinator of Research Focus "Applied and Experimental Oncology"
Group Leader
E-Mail: walter.berger [at] meduniwien [dot] ac [dot] at 
Phone:  +43 (0)1 40160 - 57555
Fax:  +43 (0)1 40160 - 957555

Research Focus

By far the majority of cancer deaths are caused by disseminated solid tumors exhibiting therapy resistance. Consequently, our translational and multidisciplinary cooperation projects focus on the development of novel therapeutic strategies in highly therapy-refractory cancers including lung cancer, mesothelioma, brain tumors and melanoma.

Thereby we aim on the:

  1. identification of genetic and molecular factors driving solid tumor aggressiveness and therapy resistance thus representing potential targets for therapeutic interventions;
  2. development of novel anticancer agents and drug combinations allowing to avoid therapy failure and resistance development.

Financial support: Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung, FWF): P19920, P17630, L212, L568, P22072
GENAU, (PLACEBO with CEMM), FFG, EU/COST (CM1105-MC), OEAD with Ukraine (National Academy of Science) and Hungary (Koranyi Institut), Herzfelder'sche Familienstiftung, Jubiläumsfonds der Österreichischen Nationalbank, Hochschuljubiläumsstiftung der Stadt Wien, Initiative Krebsforschung, Fonds des Bürgermeisters der Bundeshauptstadt Wien, Oberösterrreichische Krebshilfe, Pharmaceutical Companies

Group Members

Videos

Selected Publications

Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup.
Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, Stockhammer P, Lötsch-Gojo D, Gojo J, Gabler L, Spiegl-Kreinecker S, Doeme B, Steindl A, Klikovits T, Hoda MA, Jakopovic M, Samarzija M, Mohorcic K, Kern I, Kiesel B, Brcic L, Oberndorfer F, Müllauer L, Klepetko W, Schmidt WM, Kumar R, Hegedus B, Berger W.
Clin Cancer Res. 2020 Jul 15;26(14):3819-3830. doi: 10.1158/1078-0432.CCR-19-3573.

Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib.
Englinger B, Laemmerer A, Moser P, Kallus S, Röhrl C, Pirker C, Baier D, Mohr T, Niederstaetter L, Meier-Menches SM, Gerner C, Gabler L, Gojo J, Timelthaler G, Senkiv J, Jäger W, Kowol CR, Heffeter P, Berger W.
Int J Cancer. 2020 Sep 15;147(6):1680-1693. doi: 10.1002/ijc.32924.

Single-cell RNA-seq reveals cellular hierarchies and impaired developmental trajectories in pediatric ependymoma.
Gojo J, Englinger B, Jiang L, et al., Berger W, Kool M, Filbin MG.
Cancer Cell. 2020 Jul 13;38(1):44-59.e9. doi: 10.1016/j.ccell.2020.06.004.

Subcellular duplex DNA and G-quadruplex interaction profiling of a hexagonal Pt(II) metallacycle.
Domarco O, Kieler C, Pirker C, Dinhof C, Englinger B, Reisecker JM, Timelthaler G, García MD, Peinador C, Keppler BK, Berger W, Terenzi A.
Angew Chem Int Ed Engl. 2019 Jun 11;58(24):8007-8012. doi: 10.1002/anie.201900934.

Metal drugs and the anticancer immune response.
Englinger B, Pirker C, Heffeter P, Terenzi A, Kowol CR, Keppler BK, Berger W.
Chem Rev. 2019 Jan 23;119(2):1519-1624. doi: 10.1021/acs.chemrev.8b00396.

 

 

All Publications:

PubmedDatabase

 
Print
 
 
© MedUni Wien | Publishing information | Terms of use | Data Protection | Accessibility | Contact